EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression

Rakesh Nagarajan, John Svaren, Nam Le, Toshiyuki Araki, Mark Watson, Jeffrey Milbrandt

Research output: Contribution to journalArticle

215 Scopus citations

Abstract

The identification of EGR2 mutations in patients with neuropathies and the phenotype Egr2/Krox20-/- have demonstrated that the Egr2 transcription factor is critical for peripheral nerve myelination. However, the mechanism by which these mutations cause disease remains unclear, as most patients present with disease in the heterozygous state, whereas Egr2+/- mice are phenotypically normal. To understand the effect of aberrant Egr2 activity on Schwann cell gene expression, we performed microarray expression profiling to identify genes regulated by Egr2 in Schwann cells. These include genes encoding myelin proteins and enzymes required for synthesis of normal myelin lipids. Using these newly identified targets, we have shown that neuropathy-associated EGR2 mutants dominant-negatively inhibit wild-type Egr2-mediated expression of essential myelin genes to levels sufficiently low to result in the abnormal myelination observed in these patients.

Original languageEnglish
Pages (from-to)355-368
Number of pages14
JournalNeuron
Volume30
Issue number2
DOIs
StatePublished - Jan 1 2001

Fingerprint Dive into the research topics of 'EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression'. Together they form a unique fingerprint.

  • Cite this